Clinical Trials Sponsored by Kowa Company, Ltd.

Total 477 results

Kyowa Kirin Pharmaceutical Development Ltd

Terminated

Naloxegol Health Outcome Post Authorisation Safety Study

Opioid Induced Constipation

Netherlands, United Kingdom
Kyowa Kirin Pharmaceutical Development Ltd

Completed

A UK Multicentre, Health-Related Quality of Life Study for Children and Adolescents With XLH

X-Linked Hypophosphataemia

United Kingdom
Kyowa Kirin Pharmaceutical Development Ltd

Completed

Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH

X-linked Hypophosphatemia

United Kingdom, France, Ireland, Italy
Kyowa Kirin Pharmaceutical Development Ltd

Completed

Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients

Constipation, Signs and Symptoms, Digestive

United Kingdom, Denmark, Norway, Israel, Spain
University of Iowa
Eli Lilly and Company

Completed

Atomoxetine and Huntington's Disease

Huntington Disease | Chorea

United States
Kyowa Kirin Pharmaceutical Development Ltd

Active, not recruiting

Registry for Patients With X-Linked Hypophosphatemia (XLH Registry)

X-Linked Hypophosphatemia

Spain, Italy, United Kingdom, France, Belgium, Denmark, Germany, Hungary, Portugal, Norway, Switzerland, Israel, Netherlands, Czechia, Bulgaria, Sweden, Slovenia, Ireland, Latvia, Slovakia
Kyowa Kirin Pharmaceutical Development Ltd

Completed

Naloxegol Drug Utilization Post Authorisation Safety Study

Opioid Induced Constipation

United Kingdom, Norway, Sweden, Germany
Kyowa Kirin Pharmaceutical Development Ltd

Withdrawn

Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years

Chemotherapy Induced Nausea and Vomiting
Kyowa Kirin Pharmaceutical Development Ltd

Withdrawn

Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years

Chemotherapy Induced Nausea and Vomiting
Pfizer
Kyowa Kirin Co., Ltd.

Terminated

A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors

Advanced/Metastatic Solid Tumors

United States
Kyowa Kirin Pharmaceutical Development Ltd

Completed

Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years

Chemotherapy Induced Nausea and Vomiting

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Terminated

Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer

Colorectal Cancer

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Terminated

Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer

Neoplasms | Ovarian Neoplasms | Fallopian Tube Neoplasms | Primary Peritoneal Neoplasm

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Terminated

Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

Breast Cancer

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor

Solid Tumor

United States
Kyowa Hakko Kirin Pharma, Inc.
Kyowa Kirin Co., Ltd.

Completed

An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia

X-linked Hypophosphatemia

United States, Canada
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

A Study to Evaluate Abuse Potential of Istradefylline

Drug Abuse

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Terminated

Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma

Multiple Myeloma

United States
Kyowa Hakko Kirin Pharma, Inc.
Kyowa Kirin Co., Ltd.

Completed

A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia

X-linked Hypophosphatemia

United States, Canada
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease (KW-6002)

Idiopathic Parkinson's Disease

United States, Canada, Czechia, Germany, Israel, Italy, Poland, Serbia
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Idiopathic Parkinson's Disease

United States, Canada, Czechia, Germany, Israel, Italy, Poland, Serbia
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma

Peripheral T-Cell Lymphoma

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001

Cutaneous T-cell Lymphoma | Peripheral T-cell Lymphoma

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.

Parkinson's Disease

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States, Philippines, United Kingdom
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline

Hepatic Impairment

United States
Guangzhou Lupeng Pharmaceutical Company LTD.

Completed

The Mass Balance Study of LP-168 in Healthy Subjects

Clinical Pharmacology

China
Guangzhou Lupeng Pharmaceutical Company LTD.

Active, not recruiting

A Study of LP-128 Capsules in Healthy Subjects

Chronic Hepatitis b

China
Guangzhou Lupeng Pharmaceutical Company LTD.

Completed

A Food Effect Study of LP-168 Tablets in Healthy Subjects

Mantle Cell Lymphoma

China
Guangzhou Lupeng Pharmaceutical Company LTD.

Completed

A Study of LP-168 in Healthy Volunteers

Multiple Sclerosis | NMO Spectrum Disorder

China
Mclean Hospital
LiteBook Company Ltd

Completed

Effects of Litebook EDGE™ Phototherapy on Academic Performance and Brain Activity (LiteBook)

Sleepiness, Daytime

United States
Guangzhou Lupeng Pharmaceutical Company LTD.

Recruiting

Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

B-cell Non-Hodgkin Lymphoma

China
Guangzhou Lupeng Pharmaceutical Company LTD.

Recruiting

A Study of LP-168 in Participants With Relapse or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL)

China
Guangzhou Lupeng Pharmaceutical Company LTD.

Recruiting

A Study of LP-118 in Patients With Advanced Tumors

Lymphoma, Non-Hodgkin | Solid Tumor

China
Mochida Pharmaceutical Company, Ltd.
Pfizer

Completed

A Study of MD-120 in Patients With Depression

Major Depressive Disorder

Japan
Elmore Oil Company Pty Ltd

Completed

The Effects of Elmore Oil on Patients With Osteoarthritis

Inflammation | Degenerative Arthritis

Philippines
Kyowa Kirin Co., Ltd.
Ono Pharmaceutical Co. Ltd

Completed

Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors

Solid Tumor

Japan
Guangzhou Lupeng Pharmaceutical Company LTD.

Recruiting

A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

China
Guangzhou Lupeng Pharmaceutical Company LTD.

Recruiting

A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma

B-cell Lymphoma

China
Mochida Pharmaceutical Company, Ltd.
Fuji Yakuhin Co., Ltd.

Completed

Drug-drug Interaction Study of FYU-981 and Oxaprozin

Healthy

Japan
Fuji Yakuhin Co., Ltd.
Mochida Pharmaceutical Company, Ltd.

Completed

Study of FYU-981 in Hyperuricemia With or Without Gout

Hyperuricemia With or Without Gout

Japan
Mochida Pharmaceutical Company, Ltd.
Fuji Yakuhin Co., Ltd.

Completed

Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

Hyperuricemia With or Without Gout

Japan
Mochida Pharmaceutical Company, Ltd.
Fuji Yakuhin Co., Ltd.

Completed

Clinical Pharmacology of FYU-981 (Subjects With Hepatic Insufficiency)

Hepatic Insufficiency | Healthy

Japan
Kyowa Kirin, Inc.
Bristol-Myers Squibb

Completed

Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors

Carcinoma | HCC | Cancer | Hepatocellular Carcinoma | Solid Tumor

United States
Fuji Yakuhin Co., Ltd.
Mochida Pharmaceutical Company, Ltd.

Completed

Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

Hyperuricemia With or Without Gout

Japan
Mochida Pharmaceutical Company, Ltd.
Fuji Yakuhin Co., Ltd.

Completed

Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)

Hyperuricemia With or Without Gout

Japan
Fuji Yakuhin Co., Ltd.
Mochida Pharmaceutical Company, Ltd.

Completed

Mass Balance Study of FYU-981

Healthy Male Subjects

Japan
Mochida Pharmaceutical Company, Ltd.
Fuji Yakuhin Co., Ltd.

Completed

Clinical Pharmacology of FYU-981 (Final Formulation)

Healthy

Japan
Amgen
AstraZeneca; Kyowa Kirin Co., Ltd.

Terminated

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility

Asthma

United States, Canada, France, Germany, Italy, Taiwan, Hong Kong, Australia, Greece, Russian Federation, Poland, Ireland, Puerto Rico, Korea, Republic of, New Zealand
Fujifilm Kyowa Kirin Biologics Co., Ltd.

Completed

A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients (ARABESC-OLE)

Arthritis, Rheumatoid

Poland, Russian Federation, United States, Germany, Romania, Ukraine, Canada, Chile, Czechia, Spain, Peru

Clinical Trials Sponsored by Kowa Company, Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations